Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04215809 · ClinicalTrials.gov registry record · Phase 1

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

A Phase 1 study of CLL/SLL, sponsored by Ascentage Pharma Group.

Recruiting
Registry status
Phase 1
Development phase
144
Enrollment target
9
Study locations

NCT04215809 is a Phase 1 study of CLL/SLL that is actively recruiting participants, run by Ascentage Pharma Group. The registered enrollment target is 144 participants, above the 110-participant average among 5 other CLL/SLL trials with a reported enrollment target (31% higher). The trial reports 9 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04215809, a Phase 1 study of CLL/SLL, is actively recruiting participants, sponsored by Ascentage Pharma Group.

RECRUITING
Registry status
Phase 1
Development phase
144 participants
Enrollment target
9
Study locations

Study Summary

Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of lisaftoclax.

Conditions Studied

CLL/SLL

Interventions

  • DRUG Lisaftoclax

Study Locations (9)

Ohio

  • Gabrail Cancer Center - Canton
  • Cleveland Clinic - Cleveland

California

  • City of Hope - Duarte

Florida

  • Mayo Clinic - Jacksonville

Massachusetts

  • Dana Farber Cancer Institute - Boston

North Carolina

  • Novant Health - Charlotte

Washington

  • Swedish Health - Seattle

Queensland

  • Princess Alexandria Hospital - Brisbane

Victoria

  • Frankston Private Hospital - Melbourne

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2020-03-02
Est. Completion 2027-06-30
Phase Phase 1

Sponsor

Ascentage Pharma Group

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04215809

The ClinicalTrials.gov registry entry for NCT04215809 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 110-participant average among 5 other CLL/SLL trials with a reported enrollment target (31% higher). The listed sponsor is Ascentage Pharma Group, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with CLL/SLL appearing as the primary indexed condition, and to 1 intervention - of which Lisaftoclax is the first listed.

NCT04215809 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Ohio, California, Florida.

Frequently Asked Questions

What is clinical trial NCT04215809 about?

NCT04215809 is a clinical study titled "Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL". Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of lisaftoclax.

What is the current status of trial NCT04215809?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2020-03-02. Estimated completion is 2027-06-30.

What conditions does trial NCT04215809 study?

This clinical trial studies the following conditions: CLL/SLL.

What interventions are being tested in trial NCT04215809?

The interventions under investigation include: Lisaftoclax (DRUG).

Who is sponsoring clinical trial NCT04215809?

This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04215809 being conducted?

This trial has 9 study locations across California, Florida, Massachusetts, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for CLL/SLL

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

CLL/SLL

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.